Clinical Trial

Expanded Studies on the SCAPIS Stockholm Reexamination Cohort

Study acronym: SCAPIS-ReEx
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated March 17, 2026 (before its estimated March 30, 2026 completion). Its status may not reflect the trial's current state.
Summary
The Swedish CArdioPulmonary bioImage Study (SCAPIS) is a unique, large-scale national research initiative involving 30,000 randomly selected individuals aged 50-64, recruited between 2014 and 2018. The study is a collaborative effort among six university hospitals across Sweden. A follow-up study, SCAPIS 2, is conducted for half of the original participants. In Stockholm, 2,500 individuals will be re-examined at Danderyd University Hospital and Karolinska Institutet. SCAPIS 2 includes a core set of examinations involving blood sampling, questionnaires, and imaging. In addition to these, complementary local investigations are conducted to enable more detailed research questions. This protocol describes the additional studies conducted in the Stockholm cohort. All complementary assessments aim to identify risk factors for current and future lung, liver, and cardiovascular diseases.: EXTENDED SAMPLING: Saliva and Blood Samples with Blood Cell Isolation. EXTENDED QUESTIONNAIRES: Dyspnea, Sleep, Respiratory Infections, and Dental Health. EXTENDED IMAGING AND PHYSIOLOGICAL MEASUREMENTS Cardiac Ultrasound and Abdominal Aortic Measurements. Liver Elastography. Vascular Stiffness by cuff-based pulse wave analysis and Photoplethysmography (PPG). Valvular and Vascular Calcification by CT imaging.
Trial Details
NCT Number NCT07476703
Lead Sponsor Danderyd Hospital
Collaborators: Region Stockholm, Karolinska Institutet, Göteborg University
Conditions Coronary Artery Disease, Arterial Stiffness, Blood Pressure, AORTIC VALVE DISEASES, Mitral Valve Stenosis and/or Insufficiency, Heart Failure, Pulmonary Disease, Chronic Obstructive (COPD), Steatohepatitis, Inflammation Biomarkers +4 more
Enrollment 1,400 participants
Start Date 2024-04-08
Primary Completion 2026-03-30 (estimated)
Study Completion 2026-08-30 (estimated)
Updated on ClinicalTrials.gov 2026-03-17